Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1784MR)

This product GTTS-WQ1784MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1784MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ307MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ9088MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMCgp100
GTTS-WQ4991MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ2926MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ2692MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ7125MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ9626MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ4518MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-936557
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW